Azenta buys Barkey for €80M; expands cell & gene therapy cold-chain products

Azenta, Inc.

Purchase price approx €80M (~$86M) for Barkey, a provider of controlled-rate thawing devices.
Barkey reported ~€17M in revenue for the twelve months ended March 31, 2022.
Deal expected to close early July 2022; Barkey's owners and COO to join Azenta.
Acquisition expected accretive to non-GAAP earnings immediately and GAAP within first year.
Extends Azenta's cold-chain portfolio into cell & gene therapy, serving over 100 CGT customers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.